The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- ‘Tremendous implications’: Hospital affiliation linked to higher-cost care (Healio)
- Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients (HIT Consultant)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- SCA Health expands GI footprint, physician network in 2025 (Becker’s GI & Endoscopy)
- 7 key numbers on the state of GI in 2025 (Becker’s GI & Endoscopy)
- White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal (The Wall Street Journal)
- CADe for Colonoscopy: Positive and Negative Takeaways From Largest Real-World Study (GI & Endoscopy News)
- FDA OKs Tremfya for Ulcerative Colitis (GI & Hepatology News)